2021 QSP Virtual Symposium


Virtual Symposium Overview

This virtual symposium brings together scientists interested in quantitative systems pharmacology (QSP) to present and discuss contemporary approaches, including the challenges and opportunities for advancing the science and practice of QSP. It is hoped the symposium serves to stimulate collaborations and synergies amongst its participants to promote discoveries in the field of QSP.

The 2021 symposium is our fourth annual and, though virtual, remains a free event

We look forward to your participation!
Jim Gallo, 2021 QSP Symposium Organizer
Donald Mager, 2021 QSP Symposium Co-Organizer

On this page:


Tuesday, July 27

8:45 a.m.Welcome
9:00 a.m.Doug Lauffenburger
Systems Biology Modeling Approaches for Preclinical-to-Clinical Translation
9:45 a.m.Oleg Milberg
QSP modeling and the search for accuracy and precision: when a lot is not enough
10:30 a.m.Break
10:45 a.m.Edward Stites
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy
11:30 a.m.Stacey Finley
Predicting the impact of heterogeneity on the tumor-immune microenvironment
12:15 p.m.Break
12:20 p.m.
Trainee Speaker 1
Identification of Spike-ACE2 binding allosteric modulators using in silio method
Jingchen Zhai, University of Pittsburgh
12:35 p.m.Trainee Speaker 2
In Silico Pharmacological Assessment of Mibefradil in Single Detrusor Smooth Muscle Cell towards Understanding Urinary Bladder Over Activity
Chitaranjan Mahapatra, Cardiovascular Research Institute, University of California San Francisco
12:50 p.m.Trainee Speaker 3
Prediction of monocarboxylate transporter-mediated pharmacokinetics of gamma-hydroxybutyric acid (GHB) in patients with impaired renal function using a PBPK model
Tianjing Ren, University at Buffalo

Wednesday, July 28

8:45 a.m.Trainee Speaker 4
A New Approach for In Silico Prediction of Oral Drug Concentration Profiles in Human for Drug Candidates Lack Experimental Pharmacokinetic Data 
Beihong Ji, University of Pittsburgh
9:00 a.m.Kevin Wood
Emergence and control in microbial communities:  steering bacterial pathogens through the phenotype space of multidrug resistance
9:45 a.m.Thomas Yankeelov
Tumor Forecasting via Quantitative Imaging and Mathematical Modeling
10:30 a.m.Break
10:45 a.m.Aaron Meyer
Deeply profiling pharmacodynamic response with single cell dynamics
11:30 a.m.Ashlee Ford-Versypt
Computational Modeling of the Gut-Bone Axis and Implications of Butyrate Treatment on Osteoimmunology
12:15 p.m.Break
12:20 p.m.Kathryn Miller-Jensen
Integrating Single-Cell Measurements for Immunology


Stacey D. Finley, PhD, University of Southern California.
Stacey D. Finley, PhD, University of Southern California

Stacey D. Finley is the Gordon S. Marshall Early Career Chair and Associate Professor of Biomedical Engineering at the University of Southern California. Dr. Finley’s lab uses mathematical modeling to predict how reactions inside of cells and interactions between cells drive tumor growth.

Douglas Lauffenburger, PhD, Department of Biological Engineering, MIT.
Douglas Lauffenburger, PhD, Department of Biological Engineering, MIT

Dr. Lauffenburger is a Professor of Biomedical Engineering at the Massachusetts Institute of Technology. He is a pioneer in computational approaches at the interface of biochemistry, quantitative cell biology and engineering.

Aaron Meyer, PhD, Department of Bioengineering, UCLA.
Aaron Meyer, PhD, Department of Bioengineering, UCLA

Aaron Meyer is an Assistant Professor of Bioengineering at the University of California, Los Angeles. He combines mathematical/statistical models with quantitative cell biology to study drug response.

Oleg Milberg, PhD, Janssen Pharmaceutical.
Oleg Milberg, PhD, Janssen Pharmaceutical

Oleg Milberg is a Senior Scientist in the Translational Modeling group within the department of Clinical Pharmacology and Pharmacometrics at Janssen Pharmaceuticals. His work focuses on the design, development and application of a range of models, including QSP and systems biology, PBPK and PK/PD to help with clinical study design and dosing strategy recommendations.

Kathryn Miller-Jensen, PhD, Yale University.
Kathryn Miller-Jensen, PhD, Yale University

Kathryn is an Associate Professor of Biomedical Engineering at Yale. Before joining the faculty, she was an NIH Postdoctoral Fellow at UC Berkeley in the Schaffer laboratory. Kathryn worked previously at the National Academies, Merck Pharmaceuticals, the Chinese Academy of Sciences, and Monitor Group. She received her PhD in Chemical Engineering at MIT with Doug Lauffenburger. and her BE and BA degrees at Dartmouth College.

Edward Stites, MD, PhD, Salk Institute.
Edward Stites, MD, PhD, Salk Institute

Ed Stites is an Assistant Professor directing the Integrated Biology lab that uses mathematical and computational models to study the behaviors of genetic signaling networks implicated in cancer.

Ashlee N. Ford Versypt.
Ashlee N. Ford Versypt, PhD, University at Buffalo

Ashlee N. Ford Versypt is an Associate Professor in the Dept. of Chemical and Biological Engineering at the University at Buffalo. She leads the Systems Biomedicine and Pharmaceutics Laboratory, which develops multiscale mathematical and computational models to enhance understanding of the mechanisms governing tissue remodeling and damage as a result of diseases and infections and to simulate the treatment of those conditions.

Kevin Wood, PhD, Departments of Biophysics and Physics, University of Michigan.
Kevin Wood, PhD, Departments of Biophysics and Physics, University of Michigan

Kevin Wood is an Assistant Professor interested in quantitative biology and the dynamics of complex systems with particular emphasis on systems dominated by heterogeneity, stochasticity, strong coupling and rare events.

Thomas Yankeelov, PhD, Department of Biomedical Engineering, University of Texas.
Thomas Yankeelov, PhD, Department of Biomedical Engineering, University of Texas

Thomas Yankeelov is the W.A. "Tex" Moncrief Chair of Computational Oncology and Professor of Biomedical Engineering, Diagnostic Medicine, and Oncology at The University of Texas at Austin.  Dr. Yankeelov is the founding Director of the Center for Computational Oncology at UT Austin.  The overall goal of Dr. Yankeelov's research is to develop tumor forecasting methods by integrating advanced imaging technologies with predictive, multi-scale models of tumor growth to optimize therapy. 

Trainee Speakers

Four trainee speakers will present their QSP research and will be selected from Abstract solicitations. Trainees must be a student or postdoctoral fellow and a major contributor to the work. Please send a title, authors, affiliations, and a 150 word abstract to Jim Gallo (jmgallo@buffalo.edu) by July 1, 2021 for consideration.

Questions? Contact Us

Jim Gallo, Empire Innovation Professor, Pharmaceutical Sciences: (jmgallo@buffalo.edu